Primary AL amyloidosis and Light Chain Deposition Disease
Freelite™ serum free light chains can be identified in 98% of AL amyloidosis patients.
AL amyloidosis is a protein conformation disorder characterised by the accumulation of monoclonal free light chain fragments as amyloid deposits. For patients with either primary systemic Amyloidosis or light chain deposition disease, sensitivity of immunofixation electrophoresis (IFE) is low. These patients often do not have an M-protein peak and consequently it has been difficult to monitor their haematological response. Freelite can aid diagnosis and follow up in these patients.1
Recommendations of the UK Myeloma Forum Guidelines include:
Kaplan-Meier estimate of survival in 137 patients with AL showing a reduction of free light chain concentrations by greater than 50% following chemotherapy was associated with increased survival 2.
- "Serum free light chain assay is required for investigation in suspected AL amyloid patients".
- "Treatment strategies in individual patients are presently best guided by their early effect on quantifiable measurements of circulating free immunoglobulin light chains".
- Reduction of amyloidogenic serum free light chain concentration can suppress accumulation of AL amyloid deposits.
- Use of serum FLC (free light chain) "measurement enables response to chemotherapy to be evaluated effectively and rapidly, for example, on a monthly basis during cyclical treatments".
A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis3 states:
- "All patients should have an immunonephelometric immunoglobulin serum-free light chain assay."
- "The use of the serum free light chain assay has been important for quantification of hematologic responses and has been proposed as a useful tool to define hematologic response."
In a 2006 publication4 the authors concluded that the absolute levels of immunoglobulin free light chain appeared more relevant than the FLC ratio. Also that the achievement of a low absolute level of the involved immunoglobulin FLC was the best predictor of haematologic response, organ response and overall survival after peripheral blood stem cell transplantation.
Summary
- Serum free light chains have a circulation life of several hours compared to several weeks for intact immunoglobulin, and so can be a much earlier indicator of response to therapy5.
- Serum free light chains provide a more sensitive marker than electrophoresis and immunofixation in serum. This enables detection of most amyloidosis from a serum sample.
- Download Literature - AL Amyloidosis - Code MKG239
- Download FRENCH Literature - AL Amyloidosis - Code MKG278
Freelite Web Site
Freelite has its own web site which includes:
- Clinical Evidence for the application of Freelite in the detection and monitoring of B-cell dyscrasia
- Laboratory Protocols show the comparison of traditional methods and the new serum assays
- Guidelines - published guidelines endorsing the use of Freelite
- Products - availability of assays on a range of clinical analysers
- FAQs - frequently asked questions on the application of serum free light chain assays
References
- United Kingdom Myeloma Forum.
"Guidelines on the diagnosis and management of AL amyloidosis"
BJH 2004;125:681-700 - Helen J. Lachmann, Ruth Gallimore, Julian D. Gillmore, Hugh D. Carr-Smith, Arthur R. Bradwell, Mark B. Pepys and Philip N. Hawkins.
"Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy"
BJH 2003;122:78-84 - Morie A. Gertz, Ray Comenzo, Rodney H. Falk et al.
"Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis"
American Journal of Hematology 2005. 79:319-328 - Dispenzieri et al
'Absolute values of Free Light chains are prognostic in patients with primary amyloidosis undergoing peripheral blood stem cell transplant'
Blood 2006; 107: 3378-3383 - Ian Brockhurst, Kevin P. G. Harris, and Claire S Chapman
Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new sensitive immunoassay
Nephrol Dial Transplant 2005;20:1251-1253
Click here to order the reprints listed above (except number 5)
Freelite™ is a trademark of The Binding Site Group Ltd, Birmingham, UK
.jpg)